Mutants of gram negative mucosal bacteria and application thereof in vaccines
It is possible to inactivate the early stage of lipid A synthesis of mucosal gram negative bacteria without compromising cell viability. In particular the lpxA gene in N. meningitidis was mutated and resulting lpxA knockout mutants were found to be completely lipopolysaccharide (LPS)-deficient. The major outer membrane proteins (OMPs) were detected in normal amounts. The finding provides important implications for understanding of structure and biogenesis of the outer membrane. On a practical level, the availability of LPS-deficient mutants of pathogenic mucosal bacteria such as N. meningitidis opens up new avenues to vaccine development. It enables easy isolation of endotoxin-free purified proteins, outer membranes or even whole-cell preparations for use in immunisation.
1. A viable bacterium of the species Neisseria meningitidis, comprising a mutation in an lpxA gene, wherein said mutation causes the bacterium to lack endotoxic lipopolysaccharide (LPS).
2. The bacterium according to claim 1 , wherein the bacterium lacks Lipid A.
3. An immunogenic composition comprising a bacterium according to claim 1 , or a component part of the bacterium as active component.
4. The composition according to claim 3 , wherein the bacterium is a live attenuated bacterium.
5. The composition according to claim 3 , wherein the component part of the bacterium is an outer membrane vesicle, an outer membrane complex or an outer membrane protein.
6. The composition according to claim 3 , wherein the composition is substantially free of endotoxic LPS as determined with a Limulus assay.
7. The composition according to claim 3 , wherein the composition further comprises an adjuvant.
8. A method for producing an immunogenic composition comprising culturing a bacterium according to claim 1 , isolating the bacterium in a LPS culture and incorporating the bacterium, as an active component into said composition to produce an immunogenic composition.
9. The method according to claim 8 , further comprising incorporating an adjuvant into said composition.
10. A method for producing an LPS-free outer membrane protein from Neisseria meningitidis comprising culturing a bacterium according to claim 1 , isolating outer membrane proteins from the culture, testing the outer membrane isolated proteins to determine whether the outer membrane proteins are free of LPS, and recovering LPS-free outer membrane proteins from the culture.
11. A viable bacterium of the species Neisseria meningitidis, comprising an inactive lpxA gene or an lpxA knock-out mutant with an lpxD-fabZ-lpxA insert.
12. The bacterium according to claim 11 , wherein the bacterium lacks Lipid A.
13. An immunogenic composition comprising a bacterium according to claim 11 , or a component part of the bacterium as active component.
14. The composition according to claim 13 , wherein the bacterium is a live attenuated bacterium.
15. The composition according to claim 13 , wherein the component part of the bacterium is an outer membrane vesicle, an outer membrane complex or an outer membrane protein.
16. The composition according to claim 13 , wherein the composition is substantially free of endotoxic LPS as determined with a Limulus assay.
17. The composition according to claim 13 , wherein the composition further comprises an adjuvant.
18. A method for producing an immunogenic composition comprising culturing a bacterium according to claim 11 , testing the culture to determine whether said culture contains LPS-free bacterium, isolating said bacterium, and incorporating the bacterium, as an active component into said composition.
19. A method according to claim 18 , further comprising incorporating an adjuvant into said composition.
20. A method for producing an LPS-free outer membrane protein from Neisseria meningitidis comprising culturing a bacterium according to claim 11 isolating outer membrane proteins from the culture, testing the outer membrane isolated proteins to determine whether the outer membrane proteins are free of LPS, and recovering an LPS-free outer membrane proteins from the culture.
21. An immunogenic composition comprising a bacterium according to claim 11 .